PMID- 32429622
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 2287-979X (Print)
IS  - 2288-0011 (Electronic)
IS  - 2287-979X (Linking)
VI  - 55
IP  - 2
DP  - 2020 Jun 30
TI  - Natural soluble human leukocyte antigen class I in donor serum neutralizes 
      donor-specific HLA alloantibodies in recipient serum.
PG  - 91-98
LID - 10.5045/br.2020.2020031 [doi]
AB  - BACKGROUND: Human leukocyte antigen (HLA) molecules are cell-bound but can be 
      identified in a soluble form. These soluble HLA (sHLA) molecules have an 
      immunomodulatory function. We investigated whether natural sHLA in donor serum 
      can neutralize donor-specific HLA alloantibodies (DSAs) in recipient serum. 
      METHODS: Neutralizing effects of donor serum on DSAs in recipient serum were 
      measured using inhibition assay principle of flow cytometric crossmatch (FCXM), 
      performed using sera from 143 kidney transplant recipients and their donors. The 
      adding of donor serum to recipient serum yielded lower mean fluorescence 
      intensity (MFI) ratios (test/control) than when diluent was added [Roswell Park 
      Memorial Institute (RPMI) or third-party serum], which was presumed to be caused 
      by the neutralizing effects of sHLA. RESULTS: In the recipient group with class I 
      DSAs alone (N=14), donor serum addition to recipient serum resulted in lower T 
      cell MFI ratios [2.25 (1.31‒32.51)] than those observed on RPMI addition [3.04 
      (1.33‒125.39), P <0.05]. In the recipient group with class II DSAs alone (N=27), 
      donor serum addition showed no significant difference in B cell MFI ratios [5.03 
      (1.41‒103.53)] compared to diluent addition: RPMI [4.50 (1.34‒145.98)] or 
      third-party serum [5.08 (1.44‒138.47)], P >0.05 for both. CONCLUSION: Using 
      inhibition FCXM, we verified that natural sHLA class I in donor serum neutralizes 
      DSAs in recipient serum. However, no neutralizing effects of sHLA class II were 
      revealed in this study. These potentially beneficial effects of sHLA infused via 
      blood-derived products should be considered when desensitizing highly 
      HLA-sensitized patients.
FAU - Won, Dong Il
AU  - Won DI
AD  - Departments of Clinical Pathology, School of Medicine, Kyungpook National 
      University, Daegu, Korea.
FAU - Lee, Nan Young
AU  - Lee NY
AD  - Departments of Clinical Pathology, School of Medicine, Kyungpook National 
      University, Daegu, Korea.
FAU - Lim, Jeong-Hoon
AU  - Lim JH
AD  - Departments of Internal Medicine, School of Medicine, Kyungpook National 
      University, Daegu, Korea.
FAU - Han, Young Seok
AU  - Han YS
AD  - Departments of Surgery, School of Medicine, Kyungpook National University, Daegu, 
      Korea.
FAU - Kim, Chan-Duck
AU  - Kim CD
AD  - Departments of Internal Medicine, School of Medicine, Kyungpook National 
      University, Daegu, Korea.
FAU - Huh, Seung
AU  - Huh S
AD  - Departments of Surgery, School of Medicine, Kyungpook National University, Daegu, 
      Korea.
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Blood Res
JT  - Blood research
JID - 101605247
PMC - PMC7343548
OTO - NOTNLM
OT  - Donor-specific HLA alloantibody
OT  - Flow cytometric crossmatch
OT  - Neutralization
OT  - Soluble HLA
COIS- Authors' Disclosures of Potential Conflicts of Interest No potential conflicts of 
      interest relevant to this article were reported.
EDAT- 2020/05/21 06:00
MHDA- 2020/05/21 06:01
PMCR- 2020/06/30
CRDT- 2020/05/21 06:00
PHST- 2020/02/22 00:00 [received]
PHST- 2020/04/04 00:00 [revised]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/05/21 06:00 [pubmed]
PHST- 2020/05/21 06:01 [medline]
PHST- 2020/05/21 06:00 [entrez]
PHST- 2020/06/30 00:00 [pmc-release]
AID - br.2020.2020031 [pii]
AID - BR-55-091 [pii]
AID - 10.5045/br.2020.2020031 [doi]
PST - ppublish
SO  - Blood Res. 2020 Jun 30;55(2):91-98. doi: 10.5045/br.2020.2020031.